Buparlisib
Small molecule
Also known as BKM120
Evidence outlook · program status
Discontinued (2025-06-02), after a negative readout
Adlai Nortye's Phase 3 BURAN (NCT04338399) did not improve overall survival over paclitaxel alone in recurrent or metastatic HNSCC, and the company stopped the buparlisib programme. Novartis, the originator, had licensed global rights to Adlai Nortye in 2018. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
BELLE-2 NCT01610284 · HR+/HER2- Metastatic Breast Cancer This was a large, randomized, quadruple-blind, placebo-controlled trial with 576 participants receiving buparlisib plus fulvestrant and 571 receiving placebo plus fulvestrant. The hard clinical primary endpoint, progression-free survival, was met: median PFS was 6.9 versus 5.0 months, with hazard ratio 0.78 and p<0.001. Registry: NCT01610284 | 3 | Progression Free Survival (PFS) Based on Local Investigator Assessment - Full Analysis Set (FAS) in Full Population, Main Study Cohort and PI3K Unknown Cohort (Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to approximately 4 years) 2015-04-29 | Progression Free Survival (PFS) Based on Local Investigator Assessment - Full Analysis Set (FAS) in Full Population, Main Study Cohort and PI3K Unknown Cohort (Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to approximately 4 years): BKM120 100mg + Fulvestrant — FAS-Full population: 6.9 Months (95% CI 6.8 to 7.8); FAS-Main cohort: 6.8 Months (95% CI 5 to 7); FAS-PI3K pathway activated: 6.8 Months (95% CI 4.9 to 7.1); FAS-PI3K pathway non-activated: 6.9 Months (95% CI 4.6 to 7.2); FAS-PI3K pathway unknown: 8.7 Months (95% CI 7 to 12.4) vs Placebo + Fulvestrant — FAS-Full population: 5 Months (95% CI 4 to 5.2); FAS-Main cohort: 4.5 Months (95% CI 3.3 to 5); FAS-PI3K pathway activated: 4 Months (95% CI 3.1 to 5.2); FAS-PI3K pathway non-activated: 4.6 Months (95% CI 3.3 to 5.1); FAS-PI3K pathway unknown: 6.8 Months (95% CI 5 to 8.4) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (32)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (45)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Head and Neck Squamous Cell Carcinoma: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Buparlisib: this drug | Discontinued | Small molecule | PI3K inhibitor (pan-class I) | not yet graded | No reviewed efficacy summary in this indication | |
| Cetuximab | Approved | Monoclonal antibody | EGFR | Partial signal | NCT00122460: Overall Survival Time (OS) (time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007): Cetuximab Plus Chemotherapy 10.1 months (95% CI 8.6 to 11.2) | Chemotherapy Alone 7.4 months (95% CI 6.4 to 8.3) | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02105636: Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05) | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02358031: Primary endpoint, overall survival at a pre-specified interim analysis: pembrolizumab plus platinum/fluorouracil vs cetuximab plus platinum/fluorouracil, median 13.0 vs 10.7 months, HR 0.77; pembrolizumab alone vs cetuximab-chemotherapy in PD-L1 CPS >=1, HR 0.65 (95% CI 0.53 to 0.80) (KEYTRUDA label, KEYNOTE-048). | |
| Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj) | Approved | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| Amivantamab | Phase 3 | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| CPO301 | Phase 3 | Antibody–drug conjugate | EGFR | not yet graded | No reviewed efficacy summary in this indication | |
| NBTXR3 | Phase 3 | Nanoparticle | Hafnium-oxide nanoparticle radioenhancer | not yet graded | No reviewed efficacy summary in this indication | |
| Volrustomig | Phase 3 | Multispecific antibody | PD-1 x CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Ordastobart | Phase 2/3 | Monoclonal antibody | OX40 (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab | Phase 2 | Multispecific antibody | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Ozuriftamab Vedotin | Phase 2 | Antibody–drug conjugate | ROR2 | Partial signal | No reviewed efficacy summary in this indication | |
| ALE.P02 | Phase 1/2 | Antibody–drug conjugate | Claudin-1 (CLDN1) | not yet graded | No reviewed efficacy summary in this indication | |
| Pepinemab | Phase 1/2 | Monoclonal antibody | SEMA4D | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent